Natural history of cognitive decline in the old old

被引:68
作者
Howieson, DB
Camicioli, R
Quinn, J
Silbert, LC
Care, B
Moore, MM
Dame, A
Sexton, G
Kaye, JA
机构
[1] Oregon Hlth Sci Univ, Layton Aging & Alzheimers Dis Ctr CR131, Dept Neurol, Portland, OR 97239 USA
[2] Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA
[3] Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97239 USA
[4] Oregon Hlth Sci Univ, Dept Publ Hlth, Portland, OR 97239 USA
[5] Portland Vet Affairs Med Ctr, Portland, OR USA
[6] Univ Alberta, Dept Med Neurol, Edmonton, AB, Canada
关键词
D O I
10.1212/01.WNL.0000063317.44167.5C
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To prospectively examine the occurrence and outcome of cognitive decline in healthy, community-dwelling elders. Methods: Ninety-five elders (mean age 84 years) who at entry had no cognitive impairment were followed for up to 13 years. Cognitive decline was defined as obtaining either a Clinical Dementia Rating (CDR) = 0.5 or Mini-Mental State Examination (MMSE) score < 24 on two examinations. Results: Three outcomes of aging were determined: intact cognition, persistent cognitive decline without progression to dementia, and dementia. Whereas 49% remained cognitively intact, 51% developed cognitive decline. Mean follow-up to first CDR 0.5 was 3.8 years and age at conversion was 90.0 years. Those who remained cognitively intact had better memory at entry and were less likely to have APOE4 than those who developed cognitive decline. Of the 48 participants with cognitive decline, 27 (56%) developed dementia (CDR ≥1) a mean of 2.8 years later. Participants with cognitive decline who progressed to dementia had poorer confrontation naming at the time of their first CDR 0.5 than those with persistent cognitive decline who did not progress during follow-up. Conclusion: The old old are at high risk for developing cognitive decline but many will not progress to dementia in the next 2 to 3 years or even beyond. These findings are important for understanding the prognosis of cognitive decline and for the design of treatment trials for AD. APOE genotype is a risk factor for cognitive decline.
引用
收藏
页码:1489 / 1494
页数:6
相关论文
共 49 条
[1]   Preclinical prediction of AD using neuropsychological tests [J].
Albert, MS ;
Moss, MB ;
Tanzi, R ;
Jones, K .
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2001, 7 (05) :631-639
[2]   The impact of mild cognitive impairment on functional abilities in the elderly. [J].
Albert S.M. ;
Tabert M.H. ;
Dienstag A. ;
Pelton G. ;
Devanand D. .
Current Psychiatry Reports, 2002, 4 (1) :64-68
[3]   CORNELL SCALE FOR DEPRESSION IN DEMENTIA [J].
ALEXOPOULOS, GS ;
ABRAMS, RC ;
YOUNG, RC ;
SHAMOIAN, CA .
BIOLOGICAL PSYCHIATRY, 1988, 23 (03) :271-284
[4]   Progression to dementia in patients with isolated memory loss [J].
Bowen, J ;
Teri, L ;
Kukull, W ;
McCormick, W ;
McCurry, SM ;
Larson, EB .
LANCET, 1997, 349 (9054) :763-765
[5]   Age related cognitive decline: A clinical entity? A longitudinal study of cerebral blood flow and memory performance [J].
Celsis, P ;
Agniel, A ;
Cardebat, D ;
Demonet, JF ;
Ousset, PJ ;
Puel, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (06) :601-608
[6]  
Christensen H, 1997, INT J GERIATR PSYCH, V12, P581, DOI 10.1002/(SICI)1099-1166(199705)12:5<581::AID-GPS571>3.0.CO
[7]  
2-B
[8]   Early development and progression of dementing illness in the elderly: A general-practice based study [J].
Cooper, B ;
Bickel, H ;
Schaufele, M .
PSYCHOLOGICAL MEDICINE, 1996, 26 (02) :411-419
[9]  
Esiri MM, 2001, LANCET, V357, P169
[10]   Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease [J].
Fagan, AM ;
Watson, M ;
Parsadanian, M ;
Bales, KR ;
Paul, SM ;
Holtzman, DM .
NEUROBIOLOGY OF DISEASE, 2002, 9 (03) :305-318